Golimumab Administered Subcutaneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of the GO-RAISE Study

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/ard.2011.154799
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Safety and Efficacy of Golimumab Administered Intravenously in Adults With Ankylosing Spondylitis: Results Through Week 28 of the GO-ALIVE Study

Journal of Rheumatology
RheumatologyAllergyImmunology
2017English

Ankylosing Spondylitis--Experience With a Self Administered Questionnaire: An Analytical Study.

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1989English

Celecoxib Versus Diclofenac for the Treatment of Ankylosing Spondylitis: 12-Week Randomized Study in Norwegian Patients

Journal of International Medical Research
BiochemistryMedicineCell Biology
2016English

Sustained Durability and Tolerability of Etanercept in Ankylosing Spondylitis for 96 Weeks

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2005English

Ankylosing Spondylitis

2019English

Ankylosing Spondylitis

2019English

Ankylosing Spondylitis

2019English

Ankylosing Spondylitis

2019English

Withdrawal of Infliximab Therapy in Ankylosing Spondylitis in Persistent Clinical Remission, Results From the REMINEA Study

Arthritis Research & Therapy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy